Nexsen Limited

NXN

AU0000418782

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:04 11/06/2026 BST			5-day change	1st Jan Change
0.2300 ^AUD	0.00%		-2.13%	+43.75%

05-13	Nexsen secures first hospital partner in Asia	RE
03-31	Nexsen says HK$6 mln grant awarded to advance Asia-Pacific execution	RE

Nexsen secures first hospital partner in Asia

Published on 05/13/2026 at 02:49 am BST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Nexsen Limited

05-13	Nexsen secures first hospital partner in Asia	RE
03-31	Nexsen says HK$6 mln grant awarded to advance Asia-Pacific execution	RE
03-30	Nexsen Hong Kong Limited Receives HKD 6 Million Ignite Grant from Hong Kong Science and Technology Parks Corporation	CI
02-26	Nexsen Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-24	14,200,000 Ordinary Shares of Nexsen Limited are subject to a Lock-Up Agreement Ending on 24-FEB-2026.	CI
02-05	6,000,000 Ordinary Shares of Nexsen Limited are subject to a Lock-Up Agreement Ending on 5-FEB-2026.	CI
01-06	Trump Dreams Meet Market Reality
01-06	U.S. ambitions go down smoothly
01-06	Nexsen Ltd appoints Richard Jarvis as CFO	RE
01-05	Nexsen Limited Appoints Richard Jarvis as Chief Financial Officer	CI
01-05	Nexsen Limited Provides Business Update Highlighting the Commencement of FDA Engagement for Its GBS Rapid Sensor, Progress Towards US Market Entry	CI
12-02	Nexsen Limited Appoints Professor Shekhar Kumta as Non-Executive Director, Effective December 3, 2025	CI
21/10/25	Nexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%	MT
10/10/25	Nexsen Limited has completed an IPO in the amount of AUD 8 million.	CI
09/10/25	Nexsen Limited Auditor Raises 'Going Concern' Doubt	CI

Nexsen Limited is an Australia-based nanobiotechnology company. The Company is focused on development of proprietary biosensing platforms for rapid, high precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural and biosecurity applications. Its product pipeline includes GBS Rapid Sensor, Chronic kidney disease, and bovine mastitis. Its lead product, the GBS Rapid Sensor, is a diagnostic for the detection of human Group B Streptococcus (GBS) in expectant mothers. The Company is also developing a paper-based chronic kidney disease (CKD) test designed for early detection and routine monitoring across both clinics and at-home use. The bovine mastitis test is designed to test bovine mastitis in cows.

Employees

Sector

Biotechnology & Medical Research

More about the company